We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Angion Biomedica Signs Licensing Option with Memorial Sloan Kettering Cancer Center

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Angion Biomedica Corp. has signed an exclusive world-wide licensing option with Memorial Sloan Kettering Cancer Center in New York City (MSKCC) for a novel vaccine platform developed by Professor Samuel Danishefsky.

Professor Danishefsky is the Kettering Chair and Director of the Laboratory for Bioorganic Chemistry at the Sloan-Kettering Institute and the Centennial Professor of Chemistry at Columbia University.

The vaccine platform enables presentation of multiple carbohydrate antigens on a single synthetic scaffold and has been shown to trigger an in vivo immune response to multiple oncology related targets. The vaccine scaffold can be customized for various clinical indications and represents a major advance for immunotherapy.

A Phase I clinical trial is scheduled to start early in 2009.